AbbVie may see less pain from Humira sales decline as rival lags
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
AbbVie (ABBV) climbs after raising full-year earnings guidance
July 27, 2023 9:09 AM EDTAbbVie (NYSE: ABBV) shares are climbing premarket on the back of its second-quarter profit and revenue beat. The company also raised earnings per share guidance.
The pharmaceutical firm reported Q2 EPS of $2.91, $0.04 better than the analyst estimate of $2.87. Revenue for the quarter... More
